Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.

OBJECTIVE To characterize the effect of partially suppressive combination antiretroviral therapy on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV)-1 RNA levels and CSF inflammation. DESIGN The study was a cross-sectional analysis of 139 HIV-1-infected subjects without active neurological disease, categorized as having successful therapy (plasma HIV-1 RNA level < or =500 copies/mL), having failure of therapy (plasma HIV-1 RNA level >500 copies/mL), or not receiving therapy. The control group consisted of 48 HIV-negative subjects. CSF and plasma HIV-1 RNA assays had a lower limit of quantification of 2.5 copies/mL. Genotypic resistance testing was performed on a subset of subjects. RESULTS Of the 47 subjects with successful therapy, CSF HIV-1 RNA levels were <2.5 copies/mL in 34 (72%). Only 1 had an HIV-1 RNA level >500 copies/mL. Although plasma HIV-1 RNA levels were similar in 35 subjects with failed therapy and 57 of those not receiving therapy (P=.84), CSF HIV-1 RNA levels were at least 10-fold lower in subjects with failed therapy (P<.0001). This disproportionate effect of treatment on CSF HIV-1 RNA levels was found across the range of plasma HIV-1 RNA levels and was not explained by differences in levels of drug resistance in plasma or CSF. Therapy reduced CSF inflammation in both treated groups. CONCLUSIONS In our cohort, antiretroviral therapy had a greater effect on HIV-1 RNA levels in CSF than in plasma and reduced intrathecal inflammation, even in the presence of drug resistance.

[1]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  P. Narciso,et al.  Neuroactive Antiretroviral Drugs Do Not Influence Neurocognitive Performance in Less Advanced HIV-Infected Patients Responding to Highly Active Antiretroviral Therapy , 2006, Journal of acquired immune deficiency syndromes.

[3]  C. Petropoulos,et al.  Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment , 2005, BMC infectious diseases.

[4]  J. Martinez-Picado,et al.  Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral‐experienced HIV‐infected patients , 2005, Journal of medical virology.

[5]  R. Price,et al.  Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment , 2005, Antiviral therapy.

[6]  D. Haas,et al.  Compartmentalized Human Immunodeficiency Virus Type 1 Present in Cerebrospinal Fluid Is Produced by Short-Lived Cells , 2005, Journal of Virology.

[7]  C. Petropoulos,et al.  HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. , 2005, The Journal of infectious diseases.

[8]  D. Richman,et al.  Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy , 2005, Journal of Virology.

[9]  B. Brew,et al.  Independent Evolution of Human Immunodeficiency Virus (HIV) Drug Resistance Mutations in Diverse Areas of the Brain in HIV-Infected Patients, with and without Dementia, on Antiretroviral Treatment , 2004, Journal of Virology.

[10]  A. Mocroft,et al.  Changing incidence of central nervous system diseases in the EuroSIDA cohort , 2004, Annals of neurology.

[11]  K. Hertogs,et al.  Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration , 2003, AIDS.

[12]  R. Ransohoff,et al.  Three or more routes for leukocyte migration into the central nervous system , 2003, Nature Reviews Immunology.

[13]  P. Narciso,et al.  Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. , 2003, The Journal of infectious diseases.

[14]  C. Yoder,et al.  Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen , 2003, AIDS.

[15]  O. Lambotte,et al.  HIV‐1 Persistence, Viral Reservoir, and the Central Nervous System in the HAART Era , 2003, Brain pathology.

[16]  J. Balzarini,et al.  Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. , 2002, Antiviral research.

[17]  K. Tashima,et al.  Discordant Human Immunodeficiency Virus Type 1 drug resistance mutations, including K103N, observed in cerebrospinal fluid and plasma. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  F. Wit,et al.  Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. , 2002, AIDS.

[19]  T. Wrin,et al.  CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. , 2002, The Journal of infectious diseases.

[20]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[21]  C. Petropoulos,et al.  Cerebrospinal fluid response to structured treatment interruption after virological failure , 2001, AIDS.

[22]  W. Miller,et al.  HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health , 2001, AIDS.

[23]  R. Stingele,et al.  Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy , 2001, Neurology.

[24]  C. Boucher,et al.  Implications of antiretroviral resistance on viral fitness , 2001, Current opinion in infectious diseases.

[25]  J. Becker,et al.  HIV-associated neurologic disease incidence changes: , 2001, Neurology.

[26]  D. Cooper,et al.  Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid , 2000, AIDS.

[27]  P. Portegies,et al.  Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine , 2000, AIDS.

[28]  M. Zazzi,et al.  Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. , 2000, The Journal of infectious diseases.

[29]  D. Fuchs,et al.  Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients , 2000, Journal of Neuroimmunology.

[30]  A S Perelson,et al.  Drug concentration heterogeneity facilitates the evolution of drug resistance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Brew.  Neurological efficacy of stavudine, zidovudine, and lamivudine , 1998, The Lancet.

[32]  E. Branch,et al.  Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. , 1998, JAMA.

[33]  M. Kazatchkine,et al.  Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease , 1998, AIDS.

[34]  I. Grant,et al.  Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome , 1997, Annals of neurology.

[35]  J. McArthur,et al.  Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brain , 1997, Annals of neurology.

[36]  F. Clavel,et al.  Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. , 1997, AIDS.

[37]  P. Portegies.  HIV-1, the brain, and combination therapy , 1995, The Lancet.

[38]  B. Fadeel,et al.  V3 sequences of paired HIV-1 isolates from blood and cerebrospinal fluid cluster according to host and show variation related to the clinical stage of disease. , 1993, Virology.

[39]  R. Price,et al.  The AIDS dementia complex. , 1988, The Journal of infectious diseases.

[40]  B. Navia,et al.  The AIDS dementia complex: I. Clinical features , 1986, Annals of neurology.

[41]  R. Hughes,et al.  Immunology of the Nervous System , 1983 .

[42]  K. Williams,et al.  Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. , 2002, Annual review of neuroscience.

[43]  R. Siliciano,et al.  Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. , 2000, Annual review of immunology.

[44]  S. Amini,et al.  CNS as an HIV-1 reservoir; BBB and drug delivery. , 1999, Journal of neurovirology.

[45]  S. Deeks.  Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. , 1999, Advances in experimental medicine and biology.

[46]  J. Sidtis,et al.  Evaluation of the AIDS dementia complex in clinical trials. , 1990, Journal of acquired immune deficiency syndromes.